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Virus-like particles were produced in insect cells containing either the L1 and L2 capsid proteins of bovine papillomavirus
type 4 (BPV-4) or only the L1 protein. Both preparations of VLPs proved to be extremely effective prophylactic vaccines.
Thirteen of 15 calves immunised with either L1–L2 VLPs or L1–VLPs were refractory to experimental challenge with high
doses of BPV-4 and did not develop papillomas, while 9 of 10 control animals developed multiple oral papillomas. VLPs
were not efficient as therapeutic vaccine in calves with established papillomas, although VLP-vaccinated animals appeared
to undergo tumour regression more rapidly than nonvaccinated control animals. Antibody responses in VLP-vaccinated
calves were associated with prevention of disease but not with regression of papillomas. Thus prophylactic VLP vaccination
is effective in preventing disease in this model of mucosal papillomavirus infection. VLPs and native virus share at least
some conformational epitopes, as shown by the cross-reactivity of their antibodies. q 1996 Academic Press, Inc.
INTRODUCTION with the homologous virus, including bovine papillo-
mavirus-1 (BPV-1), BPV-2, BPV-4, and cottontail rabbit
Papillomaviruses are now recognised as carcinogenic papillomavirus (CRPV) (Pilachinski et al., 1986; Jarrett
agents in humans and animals (IARC, 1995). In addition et al., 1991; Campo et al., 1993a; Christensen et al.,
to their involvement in cancer, these viruses can cause 1991; Lin et al., 1992). Vaccination with the early pro-
life-long and debilitating diseases which greatly reduce teins E1, E2, E6, and E7 can accelerate rejection of
the quality of life in humans and cause serious agricul- papillomas induced by CRPV and BPV-4 (Selvakumar
tural and financial problems in domestic animals. There et al., 1995a,b; Campo et al., 1993a; Francoise Breit-
is therefore a need for papillomavirus vaccines which burd, personal communication), as can vaccination
can prevent or cure viral infection. Vaccination against with BPV-2 L2 (Jarrett et al., 1991).
papillomavirus has a long history (Shope, 1937). The first Immunisation with the early proteins is accompanied
vaccines were based on crude wart extracts (Shope, by cellular immune responses (McGarvie et al., 1995;
1937; Olson and Skidmore, 1959; Olson et al., 1960) or
Selvakumar et al., 1995a), deemed responsible for papil-
on purified virus (Jarrett et al., 1990). These vaccines
loma rejection. The capsid proteins elicit the production
successfully induced protection against experimental vi-
of neutralising antibodies (Jarrett et al., 1991; Christensen
rus infection and elicited the production of virus neutralis-
et al., 1991; Lin et al., 1992; McGarvie et al., 1994; Gauk-
ing antibodies in the vaccinated host (Jarrett et al., 1990).
roger et al., 1996), which in the case of bacterially ex-
However, the difficulties of producing papillomavirus in
pressed proteins may be directed against linear epi-
experimental conditions are well known, and even mod-
topes. There is however a large body of evidence that
erate amounts of virus can only be obtained from some
during natural papillomavirus infection neutralising anti-types of papillomas, usually in animals.
bodies are produced which are directed against confor-More recently viral proteins expressed in bacteria,
mational epitopes (Ghim et al., 1991) and that these playusually as fusion polypeptides, have been employed
an important part in immunity against papillomavirusas vaccines. These experiments have demonstrated
(Christensen et al., 1994b).that the structural capsid proteins L1 and L2 can inde-
Expression of L1 and L2, or L1 alone, in eukaryoticpendently protect vaccinated animals from infection
cells results in the self-assembly of the proteins into
virus-like particles (VLPs) (Zhou et al., 1991; Kirnbauer et
al., 1992; Hagensee et al., 1993; Kirnbauer et al., 1993;1 To whom reprint requests should be addressed. Fax: /141 942
6521; e-mail: s.campo@udcf.gla.ac.uk. Zhou et al., 1993). VLPs are both structurally (Hagensee
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et al., 1994) and antigenically (Kirnbauer et al., 1992; Rose fusion protein (Joan Grindlay, unpublished data), was
used to detect L1, and a hyperimmune serum derivedet al., 1993) similar to virus; they present the conforma-
tional epitopes which are necessary for induction of high from a L2 vaccinated calf (Campo et al., 1993a) was used
to detect L2. L1 VLPs and L1–L2 VLPs were producedtitre neutralising antibodies (Kirnbauer et al., 1992; Chris-
tensen et al., 1994b). Contrary to infectious virus, VLPs and purified using sucrose and CsCl gradients as de-
scribed (Kirnbauer et al., 1993). Self-assembly into VLPsdo not contain possibly oncogenic papillomavirus DNA,
which increases their attractiveness as vaccine candi- was determined by transmission electron microscopy of
purified particle preparations, following negative stainingdates (Lowy et al., 1994).
Since papillomavirus infections are species restricted, with 1% uranyl acetate (Kirnbauer et al., 1993).
vaccine trials of human papillomavirus (HPV) VLPs can-
Prophylactic vaccinationnot be done in animals, and the initial evaluation of the
effectiveness of VLP-based vaccines against papillo- Young calves, 8–12 months old, were divided into
mavirus infection can only be conducted in animal mod- three groups: group 1 contained 10 calves; group 2 and
els. VLPs of CRPV were shown to be effective as a pro- 3 initially contained 8 calves each, but a calf in group 3
phylactic vaccine against cutaneous infection in domes- developed a mouth papilloma before the beginning of
tic rabbits (Breitburd et al., 1995). Since the HPV the experiment and was withdrawn from the trial. Animals
infections most often associated with human cancer are in group 1 were not vaccinated; animals in group 2 were
mucosal, it was important to test the effectiveness of VLP vaccinated by intramuscular injection with two doses (V1
vaccines against animal mucosal papillomaviruses. BPV- and V2) 4 weeks apart of 150 mg L1 VLPs each, and
4 induces papillomas of the alimentary canal mucosa animals in group 3 with two doses of 200 mg of L1–
which can undergo malignant progression (Campo et al., L2 VLPs each. Both antigens were in aluminium gel as
1993b), thus resembling human mucosal infections. We adjuvant (Campo et al., 1993a). Two weeks after the sec-
have generated L1-L2 and L1 VLPs of BPV-4 and have ond vaccine dose (V2 / 2w), all animals were infected
evaluated their efficacy as vaccines in preventing experi- in the palate with a suspension of 1011 BPV-4 particles
mental induction of papillomas and in inducing regres- in 10 sites (1010 particles per site) as described (Campo
sion of established papillomas. et al., 1993a). The calves were examined for number
and size of papillomas at approximately 4-week intervals.
MATERIALS AND METHODS Blood was taken from each animal before vaccination
(p.i.), 1 week and 2 weeks after V2 (V2 / 1w, V2 / 2w;Preparation of VLPs
note, V2 / 2w  C, day of challenge), and 2 and 12
The complete L1 and L2 open reading frames (ORFs) weeks after virus challenge (C / 2w, C / 12w). The
of the BPV-4 genome were amplified by PCR using the serum was stored at 0707 until testing.
recombinant plasmid pBV4 (Campo and Coggins, 1982)
as DNA template and oligonucleotide primers incorporat- Therapeutic vaccination
ing restriction sites as described (Kirnbauer et al., 1993).
Thirteen calves were infected with BPV-4 in the palateThus BPV-4 L1 ORF was amplified and cloned into the
as described above. Six weeks after infection (C/ 6w) allBglII site of pEVmod single expression or of pSynwtVI-
calves had well-developed papillomas. They were thendouble expression baculovirus vectors under the control
divided into two groups of six and seven animals, respec-of the polyhedrin promoter (forward primer, 5*-BglII-gc
tively. Group 1 was the control, while animals in groupggt aga tct atg tct ttc tgg gtt cca aat tct gc-3*; reverse
2 were inoculated with two doses of 100 mg each of L1–primer, 5*-BglII-cc gct aga tct gct cat act gct gca ggt gtt
L2 VLPs in incomplete Freund’s adjuvant, 2 weeks apart.ggc ag-3*). Similarly, the L2 ORF was amplified and
The calves were examined for number and size of papil-cloned into the SstII site of pSynwtVI-, under the control
lomas at approximately 4-week intervals. Blood wasof the promoter pSyn (forward primer, 5*-BglII-gc ggt ccg
taken before virus challenge (p.i.), before vaccination (Ccgg aat atg gtt cgt gca gca aga cg-3*; reverse primer, 5*- / 6w), and after vaccination at 3- to 6-week intervals.BglII-cc gct ccg cgg gca gaa ttt gga acc cag aaa gac-
Serum samples were stored at 0707 until testing.3*). The recombinant plasmids were sequenced across
the vector–BPV DNA junctions to ensure correct cloning
ELISA
and then cotransfected with baculovirus DNA (Baculo-
Gold, PharMingen, San Diego, CA) into Sf9 cells. Recom- Cattle sera were tested in duplicate 10-fold serial
dilutions (1001 to 1006 for VLP-vaccinated animals andbinant baculovirus clones were plaque purified as de-
scribed (Kirnbauer et al., 1993). L1 and L2 protein expres- 1001 to 1003 for control animals) against L1 – L2 VLPs.
The same sera were tested in duplicate doubling dilu-sion in Sf9 cells was verified by analysis of protein
extracts or purified VLPs by SDS–PAGE and Coomassie tions (from 1:2 to 1:256) against BPV-4 GST-L2a, GST-
L2b, and GST-L2c. GST-L2a, GST-L2b, and GST-L2cstaining or by Western blotting. A rabbit antiserum, raised
against a bacterially produced BPV-4 L1-bgalactosidase correspond to the N-terminus, middle portion, and C-
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pression baculovirus carrying the L1 and L2 ORFs. West-
ern blots of insect cell lysates were analysed with an
anti-L1 rabbit antiserum and an anti-L2 bovine antiserum,
and the expected bands of 55–60 kDa for L1 and 100 kDa
for L2 were detected (data not shown). Self-assembly
FIG. 1. Electron micrographs of (A) L1–L2 BPV-4 VLPs and (B) BPV- of L1–L2 or L1 alone into particles was confirmed by
4 virus, both purified by density gradient centrifugation. Magnification electronmicroscopy (Fig. 1A). The particles were morpho-
is 1150,000.
logically similar to BPV-4 virus (Fig. 1B).
terminus of the BPV-4 L2 protein expressed in Esche- VLPs vaccination prevents development of papillomas
richia coli as fusion products of glutathione S-trans-
In the control nonvaccinated group 9 of 10 calves de-ferase (Campo et al., 1993a). After 0.35 mg/well of L1 –
veloped papillomas 4 weeks after infection and the papil-L2 VLPs or 1 mg/well each of gel-purified GST-L2a,
lomas were still growing 21 weeks after infection (Fig.GST-L2b, and GST-L2c were attached to ELISA plates,
2). On the contrary all the calves (8 of 8) vaccinated withanalyses were carried out as described (Chandrachud
L1 VLPs were protected against challenge with BPV-4et al., 1994, 1995; Kirnbauer et al., 1994). The second
and were still papilloma-free 21 weeks after infectionanti-bovine IgG antibody was rabbit F(ab*)2 conjugated
(Fig. 2). Five of the 7 calves vaccinated with L1–L2 VLPswith horseradish peroxidase (Axell) for the analysis of
were free of papillomas during the whole course of theantibodies against VLPs and goat anti-bovine IgG con-
experiment; two calves developed one papilloma each 8jugated with alkaline phosphatase (Dynatech) for the
weeks after challenge, and 21 weeks after challenge 1analysis of antibodies against the GST-fusion peptides.
of the 2 calves developed a second papilloma (Fig. 2).Appropriate controls of antigen only, antibody only, or
The papillomas of both animals were smaller than thoseconjugate only were carried out for each serum sample.
in the control animals (not shown). We conclude thatReadings from control wells were negligible; samples
vaccination with VLPs protected from viral challenge andwere considered positive when their OD readings were
prevented papilloma development.0.1. Titres were defined as the reciprocal of the high-
est serum dilution giving a positive reading.
Humoral response to VLPs in VLP-vaccinated and
Proliferation assays virus-vaccinated calves
Fifty millilitres of blood was removed from each animal
Sera from VLP-vaccinated animals and from two ani-at appropriate intervals throughout the trial. Blood was
mals vaccinated with BPV-4 in an earlier trial (Jarrett etseparated on Lymphoprep (Nycomed UK) and peripheral
al., 1990) were tested and compared for antibodies toblood mononuclear cells (PBM) were removed from the
VLPs in ELISA (Fig. 3A). The only sera samples availableinterface and stored in liquid nitrogen. Proliferation
for the virus-vaccinated animals were preimmune (p.i.),assays were performed as described (McGarvie et al.,
V2 / 2w(C), and C / 5w. None of the animals had anti-1995). PBM at 31 105 cells per well in RPMI 1640 (Biolog-
bodies to VLPs before vaccination (p.i.). Anti-VLP antibod-ical Industries) supplemented with 10% heat-inactivated
ies were detectable at V2 / 1w in all the animals vacci-FCS (Advanced Protein Products Ltd.) and 50 mM mer-
nated with L1–L2 VLPs or with L1 VLPs. At V2 / 2w(C),captoethanol (Sigma) were cultured in medium alone or
in the presence of 1 mg GST-L2a, or 5 mg of GST-L2b,
GST-L2c, GST, or concanavalin A (Sigma). Cells were
cultured at 377 for a total of 72 hr with 1 mCi/well methyl-
[3H]thymidine for the last 6 hr. Cells were then harvested
with an automatic cell harvester (LKB) and incorporation
was counted with a betaplate counter (Wallac). Each
assay was performed in triplicate and results were aver-
aged. The results are presented as a stimulation index
(SI); SI  cpm of fusion peptide/cpm of GST alone. Given
the relatively high SI values in PBM from preimmune
animals, only SI  5 were considered positive. The stan-
dard error was less than 110 of the SI for all measurements.
RESULTS
Expression of BPV-4 L1 and L2 in insect cells and
production of VLPs
FIG. 2. Numbers of palate papillomas in control calves (1–10) and
Sf9 insect cells were infected with a single expression in calves prophylactically vaccinated with L1 VLPs (11–18) and L1–L2
VLPs (19–25), at 21 weeks after experimental challenge with BPV-4.baculovirus carrying the BPV-4 L1 ORF or a double ex-
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FIG. 3. (A) Humoral immune response to BPV-4 VLPs in VLP-vaccinated calves and virus-vaccinated calves. Each symbol represents an individual
animal. The first column at each time point represents titres of anti-VLP antibody in calves vaccinated with L1–L2 VLPs, and the second column,
titres of anti-VLP antibody in calves vaccinated with L1 VLPs. The third column at V2 / 2w(C) and the single column at C / 5w represent the titres
of anti-VLP antibodies in two virus-vaccinated calves. The antigen on the ELISA plates was L1–L2 VLPs. (B) Antibody titres to L2 in VLP-vaccinated
calves and (C) in virus-vaccinated calves. At each time point, the first column represents titres to L2a (the N-terminus of L2), the second column
titres to L2b (its internal portion), and the third column titres to L2c (its C-terminus). Each symbol represents an individual animal. The data shown
are representative of two independent measurements.
the antibody titre had increased more than one log in roger et al., 1996). In L2 vaccinated animals the antibody
response is directed to the N- and C-termini, L2a andboth groups of VLP-vaccinated animals; titres did not
appreciably change after BPV-4 infection (C / 2w). At C L2c, respectively, with little or no response to the middle
portion, L2b (Chandrachud et al., 1995). We monitored/ 12w, antibody titres had started to decline. Of the
two virus-vaccinated calves, one had a relatively high the antibody response to the three portions of L2 in both
L1–L2 VLP- and virus-vaccinated animals. Sera fromantibody titre in the VLP ELISA both before and after
challenge, comparable to the titre in the VLP-vaccinated VLP-vaccinated calves reacted poorly with L2a and L2c,
but a weak response to L2b was observed, particularlyanimals, while the other reacted poorly. These results
indicated that at least some antigenic determinants are at V2 / 2w (Fig. 3B). In contrast, sera from the two virus-
vaccinated calves responded modestly to L2a and L2cshared between BPV-4 virions and BPV-4 VLPs. Sera
from nonvaccinated infected control animals did not re- but not at all to L2b (Fig. 3C).
act in the VLP ELISA (data not shown), indicating that
Cellular response to L2 peptides in VLP-vaccinatedBPV-4 is poorly immunogenic when experimentally deliv-
calvesered in the palate.
Given the differences in antibody response to the threeHumoral response to L2 peptides in VLP-vaccinated
fragments of L2 between virus- and VLP-vaccinatedand virus-vaccinated calves
calves, the cellular response to the L2 peptides was
investigated in the latter. PBM from five calves vacci-Vaccination with bacterially expressed L2 protein of
BPV-4 elicits the production of virus neutralising antibod- nated with L1–L2 VLPs were assayed for their ability to
respond to the three fragments of L2 in proliferationies and prevents infection (McGarvie et al., 1994; Gauk-
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FIG. 4. PBM proliferation in vitro to L2. Proliferation is expressed as FIG. 5. Mean number of papillomas ({ SEM) in control calves and in
calves inoculated with L1–L2 VLPs 6 and 8 weeks after virus challenge.stimulation index (SI). Columns as in Figs. 3B and 3C.
assays up to C / 2w (Fig. 4). There was little or no were tumour-free, the differences between the two
response to the three L2 fragments at p.i., V2 / 2w(C), groups were small and not statistically significant (Fi-
and C / 2 days (C / 2d not shown). At C / 2w PBM scher’s exact test, P  0.16).
from two of the five animals responded to both L2b and
L2c, PBM from an additional animal responded to L2b Humoral response to VLPs in calves therapeutically
only, and PBM from a fourth animal responded modestly vaccinated with VLPs.
to L2a (Fig. 4). PBM from five infected control calves did
The calves vaccinated therapeutically with L1– L2not respond to any of the three L2 peptides, with the
VLPs were analysed for their immune response to theexception of PBM from two calves which responded to
antigen. The presence of serum antibodies to VLPs wasL2b at C / 2w (data not shown). A comparison with
determined by ELISA in sera taken before challenge (p.i.),virus-vaccinated calves could not be carried out, as no
at C / 6w (before vaccination), and at 3- to 6-week inter-PBM from these animals were available.
vals thereafter (Fig. 6). Although all vaccinated and con-
trol calves had papillomas by C / 6w, none of themTherapeutic vaccination with VLPs.
had a measurable antibody response to VLPs, with the
Vaccination of calves with BPV-2 L2 induced regres- exception of a single vaccinated animal with a low anti-
sion of skin warts (Jarrett et al., 1991); regression of skin body titre. However, all vaccinated calves had sero-con-
warts or alimentary canal papillomas was also occasion- verted by C / 10w; all the control animals remained
ally observed when papilloma-bearing calves were vacci- negative (not shown), confirming the poor immunogenic-
nated with BPV-2 or BPV-4 virus, respectively (WFH Jar- ity of both BPV-4 inoculum and BPV-4 progeny. VLP titres
rett, unpublished observations). To determine if BPV-4 were still high in the vaccinated animals at C / 14w, but
VLPs induced papilloma rejection, calves were infected the number and size of papillomas was not affected (Fig.
with BPV-4 as described. Six weeks after viral challenge
(C / 6w) all animals had developed papillomas; six
calves were kept as control and seven calves were im-
munised with two doses of VLPs 2 weeks apart. The
calves were monitored approximately every 4 weeks until
Week 35 after challenge (Fig. 5). At C/ 6w, the number of
papillomas was similar in the two groups and increased
slightly in both groups up to C / 14w. At C / 20w one
of the vaccinated calves had undergone rejection and
was papilloma-free. At C / 26w the number of papillo-
mas was decreasing in the two groups, but total rejection
was observed in two calves in the vaccinated group only.
Tumour regression proceeded during the next 9 weeks:
one animal in the control group and three in the vacci-
nated group were papilloma-free at C / 32w; at C /
35w two control calves and four vaccinated calves had FIG. 6. Humoral immune response to BPV-4 VLPs in calves vacci-
undergone complete rejection. Although regression nated therapeutically with VLPs. Each symbol represents an individual
animal.started earlier in the vaccinated group and more animals
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5). Thereafter in most animals titres did not appreciably nated calves than in control animals. The difference be-
tween the two groups, although suggestive of achange, even during the rejection period, and there was
no correlation between titres and regression. therapeutic effect, is too small to be statistically signifi-
cant. These results are similar to those obtained with
BPV-2 or BPV-4 virus vaccines, when regression of skinDISCUSSION
warts or alimentary canal papillomas respectively was
observed in some, but not all, animals (WFH Jarrett, un-In this study, we have explored the vaccination poten-
tial of L1 and L1–L2 VLPs in the prevention and treatment published observations). Larger groups of animals, such
as those used for the investigation of E7 as a therapeuticof mucosal infection by BPV-4. VLP vaccination efficiently
prevented the development of experimentally induced vaccine (Campo et al., 1993a), would be needed to sub-
stantiate any therapeutic effect of VLP vaccination. Vacci-papillomas, while the effect of VLPs on established papil-
lomas was equivocal. nation with VLPs, whether given before or after viral chal-
lenge, induced a vigorous antibody immune response toVaccination with native BPV-4 prevents development
of papillomas of the alimentary canal mucosa (Jarrett the antigen (cf. Figs. 3A and 6), showing that VLPs are
efficient at presenting epitopes to the humoral effectoret al., 1990), leading to the prediction that vaccination
with BPV-4 VLPs would be equally effective. Although arm of the immune system in the natural host of a papillo-
mavirus. However, although anti-VLP (or anti-virus) anti-it has recently been shown that vaccination with CRPV
VLPs prevents cutaneous papillomas in rabbits (Breit- bodies are presumably neutralising and therefore re-
sponsible for protection from disease (Breitburd et al.,burd et al., 1995), the efficacy of vaccination with VLPs
against a mucosal papillomavirus had not been estab- 1995; Suzich et al., 1995), the same antibodies do not
appear to have a role, or not a clearly definable one, inlished. Given the clinical relevance of mucosal HPV
infection, the need for an appropriate vaccine and the papilloma regression.
The epitopes presented by VLPs are shared, at leastpossibly critical differences between mucosal and cu-
taneous immunity (Roche and Crum, 1991), it was im- partially, with native virus, as antisera from virus-vacci-
nated calves recognise VLPs. Similar results have pre-portant to validate the VLP approach in a mucosal papil-
lomavirus system. viously been observed with other papillomavirus types
and their respective VLPs (Kirnbauer et al., 1994; Chris-The successful prophylaxis described here shows that
VLP vaccination can provide a high level of protection tensen et al., 1994a, b; Suzich et al., 1995).
While intramuscular vaccination with VLPs or virusalso against mucosal papillomavirus infections. This con-
clusion is supported by a recent prophylactic vaccine elicited a humoral immune response, intraoral inocula-
tion of challenge virus failed to do so, and no detectabletrial with VLPs of canine oral papillomavirus (COPV), in
which protection of dogs from experimental oral chal- response to virus or VLPs was observed in nonvacci-
nated control animals, even when they were bearing pap-lenge by COPV was observed (Suzich et al., 1995).
Both L1–L2 VLPs and L1 VLPs were effective as pro- illomas producing progeny virus. In the course of our
studies on vaccination and immunity against BPV, wephylactive vaccines. None of the animals vaccinated with
L1 VLPs developed papillomas, confirming the conclu- have repeatedly observed this lack of antibody response
to challenge or progeny virus during the first stages ofsions from the CRPV study (Breitburd et al., 1995) that the
presence of L2 in VLPs is not necessary for prevention of infection. A response to capsid proteins or to the early
protein E7 has been observed in some animals at laterdisease. Vaccination with L2 alone however can prevent
papilloma development both in the BPV-4 and CRPV sys- stages of infection and appears to be associated with
natural rejection (Chandrachud et al., 1994; Knowles ettems (Christensen et al., 1991; Lin et al., 1992; Campo et
al., 1993a), and it thus appears that immunity from dis- al., in preparation). The reasons for the failure of the
immune system to recognise incoming virus, even whenease can be elicited by at least two different viral anti-
gens. Two of the animals vaccinated with L1–L2 VLPs injected intradermally in heavy doses, are not clear. Two
possible factors are the lack of adjuvant in the inoculumdid develop one or two small papillomas, respectively.
We do not consider this to imply that L1–L2 VLPs are and the administration of a single dose. The absence of
a response to progeny virus until much later in infectionless effective than L1 VLPs. In our experience, a few
vaccinated animals, independently of the nature of the may be explained by the fact that papillomas are re-
stricted to the epithelium and therefore somewhatvaccine or of the adjuvant, may develop a negligible num-
ber of papillomas which often regress while still in the shielded from immunological recognition.
We have shown that vaccination with BPV-4 L2 or itsfirst stages of growth. Whether this implies that preven-
tion of disease is not always due to prevention of infec- N-terminus prevents induction of papillomas (Campo et
al., 1993a; Chandrachud et al., 1995). Therefore we exam-tion remains to be established.
Vaccination with L1–L2 VLPs of calves with estab- ined the antibody response to three fragments of L2 in
VLP- and virus-vaccinated animals, to see to what extentlished infection did not appear to induce papilloma re-
gression although regression started earlier in vacci- L2 is presented by native virus or VLPs and whether the
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can protect against experimental CRPV infection. J. Virol. 69, 3959–response is comparable in the two groups of vaccinated
3963.animals. Nonvaccinated animals had no detectable anti-
Campo, M. S., and Coggins, L. W. (1982). Molecular cloning of bovine
L2 antibodies, confirming previous results (McGarvie et papillomavirus genomes and comparison of their sequence homol-
al., 1994; Chandrachud et al., 1995; Knowles et al., in ogy by heteroduplex mapping. J. Gen. Virol. 63, 255–264.
Campo, M. S., Grindlay, G. J., O’Neil, B. W., Chandrachud, L. M., McGar-preparation). In contrast, a response to L2, albeit weak,
vie, G. M., and Jarrett, W. F. H. (1993a). Prophylactic and therapeuticcould be detected in vaccinated calves. Titres were gen-
vaccination against a mucosal papillomavirus. J. Gen. Virol. 74, 945–erally low, but comparable between VLP- and virus-vacci-
953.
nated calves (cf. Figs. 3B and 3C). Therefore L2, although Campo, M. S., O’Neil, B. W., Barron, R. J., and Jarrett, W. F. H. (1993b).
a good immunogen when administered intramuscularly Experimental reproduction of the papilloma-carcinoma complex of
the alimentary canal in cattle. Carcinogenesis 15, 1597–1601.as a subunit vaccine, is not well presented by vaccine
Chandrachud, L. M., Grindlay, G. J., McGarvie, G. M., O’Neil, B. W.,virus or vaccine VLPs. Indeed, in VLP-vaccinated calves
Wagner, E. R., Jarrett, W. F. H., and Campo, M. S. (1995). Vaccinationthe cellular response to L2 is detected only after virus
of cattle with the N-terminus of L2 is necessary and sufficient for
challenge, similar to what was already observed in L2- preventing infection by bovine papillomavirus-4. Virology 211, 204–
vaccinated animals (Chandrachud et al., 1995). 208.
Chandrachud, L. M., O’Neil, B. W., Jarrett, W. F. H., Grindlay, G. J.,A qualitative difference in the antibody response to L2
McGarvie, G. M., and Campo, M. S. (1994). Humoral immune re-was observed between VLP- and virus-vaccinated ani-
sponse to the E7 protein of bovine papillomavirus type 4 and identifi-mals. While virus-vaccinated animals, like L2-vaccinated
cation of B-cell epitopes. Virology 200, 98–104.
animals (Chandrachud et al., 1995), mount an antibody Christensen, N. D., Hopfl, R., DiAngelo, S. L., Cladel, N. M., Patrick,
response to the N-terminus and C-terminus of the pro- S. D., Welsh, P. A., Budgeon, L. R., Reed, C. A., and Kreider, J. W.
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antibodies. J. Gen. Virol. 75, 2271–2276.
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chud et al., 1995). Jenson, A. B., and Kreider, J. W. (1994b). Human papillomavirus type
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nor structural variations among virus isolates and VLP tains antibody-inducing neutralizing epitopes. Virology 181, 572–579.
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Ghim, S., Christensen, N. D., Kreider, J. W., and Jenson, A. B. (1991).
analysis of several different preparations of both. Anti- Comparison of neutralization of BPV-1 infection of C127 cells and
bodies to the middle portion of L2 in VLP-vaccinated bovine fetal skin xenografts. Int. J. Cancer 49, 285–289.
Ghim, S., Young, R., and Jenson, A. B. (1996). Antigenicity of bovineanimals are unlikely to contribute to protection from virus
papillomavirus type 1 virus-like particles compared with that of intactchallenge, as virus neutralising anti-L2 antibodies are
BPV-1 virions. J. Gen. Virol. 77, 183–188.directed against the N-terminus of the protein (Chandra-
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